title: Long-term potentiation of glutamatergic synaptic transmission induced by activation of presynaptic P2Y receptors in the rat medial habenula nucleus.
abstract: A novel form of long-term potentiation of glutamatergic synaptic transmission is described in the rat medial habenula nucleus. It occurs when uridine 5'-triphosphate is bath applied at low micromolar concentrations and is prevented by Reactive Blue 2, suggesting that it is mediated by P2Y4 receptors. Uridine 5'-diphosphate can also cause such a Reactive Blue 2-sensitive potentiation, but at higher concentrations (200 microm), suggesting that this might also be an effect on the relatively uridine 5'-diphosphate-insensitive P2Y4 receptor. The potentiation is due to an increase in presynaptic release probability. It requires neither depolarization nor calcium influx postsynaptically and is thus probably non-Hebbian. When potentiation due to low concentrations of uridine 5'-triphosphate is inhibited in the presence of Reactive Blue 2, uridine 5'-triphosphate causes instead a significant inhibition of glutamate release. We suggest that this inhibition may be mediated by a Reactive Blue 2-insensitive P2Y2-like receptor. At higher concentrations of uridine 5'-triphosphate (200 micro m), the inhibitory effect dominates such that even in the absence of Reactive Blue 2 no potentiation is seen.
authors.affiliation: Department of Physiology, University College London, Gower St, London WC1E 6BT, UK.
authors.forename: Gareth D
authors.initials: GD
authors.lastname: Price
authors.forename: Susan J
authors.initials: SJ
authors.lastname: Robertson
authors.forename: Frances A
authors.initials: FA
authors.lastname: Edwards
mesh_terms: D018750:6-Cyano-7-nitroquinoxaline-2,3-dione / Q000494:pharmacology; D000818:Animals; D000831:Animals, Newborn; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004558:Electric Stimulation / Q000379:methods; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005071:Evoked Potentials / Q000187:drug effects / Q000528:radiation effects; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology; D018698:Glutamic Acid / Q000378:metabolism*; D019262:Habenula / Q000166:cytology / Q000187:drug effects / Q000378:metabolism / Q000502:physiology*; D066298:In Vitro Techniques; D017774:Long-Term Potentiation / Q000502:physiology* / Q000528:radiation effects; D018408:Patch-Clamp Techniques / Q000379:methods; D017729:Presynaptic Terminals / Q000187:drug effects / Q000502:physiology* / Q000528:radiation effects; D051381:Rats; D017207:Rats, Sprague-Dawley; D018048:Receptors, Purinergic P2 / Q000502:physiology*; D058473:Receptors, Purinergic P2Y2; D009435:Synaptic Transmission / Q000187:drug effects / Q000502:physiology* / Q000528:radiation effects; D014227:Triazines / Q000494:pharmacology; D014530:Uridine Diphosphate / Q000494:pharmacology; D014544:Uridine Triphosphate / Q000494:pharmacology
chemical_list: D004791:Enzyme Inhibitors; D018691:Excitatory Amino Acid Antagonists; C546387:P2ry2 protein, rat; D018048:Receptors, Purinergic P2; D058473:Receptors, Purinergic P2Y2; D014227:Triazines; D018698:Glutamic Acid; D014530:Uridine Diphosphate; C012842:Cibacron Blue F 3GA; D018750:6-Cyano-7-nitroquinoxaline-2,3-dione; D014544:Uridine Triphosphate